{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Bristol Myers Squibb Co. technically bullish or bearish?
As of October 31, 2025, Bristol Myers Squibb Co. shows a mildly bearish technical trend with weak momentum, underperforming the S&P 500 year-to-date by -18.64% compared to its 16.30% gain.
Is Bristol Myers Squibb Co. technically bullish or bearish?
As of October 31, 2025, Bristol Myers Squibb Co. shows a mildly bearish trend, influenced by daily moving averages and bearish signals from KST and Bollinger Bands, while underperforming the S&P 500 with a year-to-date return of -18.55%.
Is Bristol Myers Squibb Co. technically bullish or bearish?
As of October 31, 2025, Bristol Myers Squibb Co. has a mildly bearish trend, with mixed signals from technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -18.55% versus the S&P 500's 16.30%.
Bristol Myers Squibb Stock Hits Day High with 7.09% Surge
Bristol Myers Squibb Co. saw a notable increase in stock performance on October 30, 2025, reaching an intraday high. The company has demonstrated resilience with a solid annual net sales growth rate and strong operating cash flow, alongside high institutional ownership, indicating investor confidence.
Bristol Myers Squibb Co. Hits New 52-Week Low at $42.52
Bristol Myers Squibb Co. has reached a new 52-week low, reflecting significant stock volatility. With a market capitalization of approximately USD 127,940 million, the company has a P/E ratio of 15.00 and a high dividend yield of 80.34%. Its return on equity stands at 51.19%, while the debt-to-equity ratio is 2.05.
Bristol Myers Squibb Stock Hits Day High with Strong Intraday Performance
Bristol Myers Squibb Co. has seen a significant rise in stock performance, reaching an intraday high and outperforming the S&P 500 in one-day metrics. Despite a challenging year-to-date performance, the company reported strong operational metrics and high institutional ownership, reflecting investor confidence.
Bristol Myers Squibb Co. Experiences Revision in Stock Evaluation Amid Market Dynamics
Bristol Myers Squibb Co. has recently revised its evaluation amid fluctuating market conditions. The stock, currently priced at $44.12, has shown volatility over the past year. Technical indicators present mixed signals, and the company has underperformed compared to the S&P 500, necessitating careful observation of its market dynamics.
Is Bristol Myers Squibb Co. technically bullish or bearish?
As of September 26, 2025, Bristol Myers Squibb Co. shows a mildly bearish trend, with mixed technical indicators and significant underperformance against the S&P 500, reflecting a year-to-date return of -21.99%.
Is Bristol Myers Squibb Co. technically bullish or bearish?
As of July 7, 2025, Bristol Myers Squibb Co. shows a mildly bearish technical trend, with mixed signals from indicators like MACD and Bollinger Bands, and a year-to-date decline of 19.38% compared to the S&P 500's gain of 12.22%.
Is Bristol Myers Squibb Co. overvalued or undervalued?
As of July 31, 2025, Bristol Myers Squibb Co. is considered very attractive due to its undervalued P/E ratio of 15, favorable EV to EBITDA ratio of 9.01, and high ROE of 49.65%, despite underperforming the S&P 500 with a year-to-date return of -19.38%.
Is Bristol Myers Squibb Co. technically bullish or bearish?
As of May 15, 2025, the technical trend is mildly bearish, indicated by a bearish MACD, moving averages, and momentum indicators, despite a bullish RSI on the weekly chart.
Is Bristol Myers Squibb Co. overvalued or undervalued?
As of April 24, 2025, Bristol Myers Squibb Co. is fairly valued with a P/E ratio of 15, outperforming the S&P 500 with an 11.90% return over the past year, while its valuation metrics compare favorably to peers like Eli Lilly & Co. and Merck & Co. Inc.
Who are in the management team of Bristol Myers Squibb Co.?
As of March 2022, Bristol Myers Squibb Co.'s management team includes Dr. Giovanni Caforio as Chairman and CEO, and Dr. Vicki Sato as Lead Independent Director, along with independent directors Peter Arduini, Robert Bertolini, Michael Bonney, and Matthew Emmens.
What does Bristol Myers Squibb Co. do?
Bristol Myers Squibb Co. is a large-cap biopharmaceutical company involved in the discovery, development, and sale of pharmaceutical products. As of March 2025, it reported net sales of $11.2 billion and a net profit of $2.5 billion.
How big is Bristol Myers Squibb Co.?
As of Jun 18, Bristol Myers Squibb Co. has a market capitalization of $129.32 billion, with recent net sales of $47.64 billion and a net profit of $5.44 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
